注册 English

Design, synthesis, and biological evaluation of N-hydroxycinnamamide/salicylic acid hybrids as histone deacetylase inhibitors

Tao You ,  Ke Chen ,  Fei-Hai Wang ,  Pi-Hong Li ,  Li-Yi Li ,  Zhi-Hao Wu ,  Kong-Hai Ni ,  Zhi-Qiang Zheng

downloadPDF
Citation:  Tao You, Ke Chen, Fei-Hai Wang, Pi-Hong Li, Li-Yi Li, Zhi-Hao Wu, Kong-Hai Ni, Zhi-Qiang Zheng. Design, synthesis, and biological evaluation of N-hydroxycinnamamide/salicylic acid hybrids as histone deacetylase inhibitors[J]. Chinese Chemical Letters, 2014, 25(3): 474-478. doi: 10.1016/j.cclet.2013.11.039 shu

Design, synthesis, and biological evaluation of N-hydroxycinnamamide/salicylic acid hybrids as histone deacetylase inhibitors

    • 通讯作者: Zhi-Qiang Zheng,
摘要: Novel histone deacetylase (HDAC) inhibitors 9a-1 were designed and synthesized by coupling the carboxyl group of salicylic acid (SA) with N-hydroxycinnamamides through various alkylol amines, and their in vitro biological activities were evaluated. The N-hydroxycinnamamide/SA hybrids 9b-f and 9h showed good to moderate anti-tumor activities. Notably, compound 9e had a greater potency, comparable to vorinostat (SAHA), in human colon carcinoma cells, which was probably, or at least partially, attributable to the positive effects of the chain length noted in alkylol amines. Furthermore, the HDAC inhibitory activities of 9e against Hela cell nuclear were also similar to that of vorinostat (SAHA), while the tested compounds 9c-f did not exhibit any isoform selectivity in the inhibition of HDACs. In addition, compound 9e could selectively inhibit tumor cells, but not inhibit non-tumor cell proliferation in vitro. Our findings suggest that the N-hydroxycinnamamide/SA hybrids may hold significant promise as therapeutic agents for the intervention of human cancers.

English

  • 

    1. [1] T.K. Kelly, D.D. de Carvalho, P.A. Jones, Epigenetic modifications as therapeutic targets, Nat. Biotechnol. 28 (2010) 1069-1078.[1] T.K. Kelly, D.D. de Carvalho, P.A. Jones, Epigenetic modifications as therapeutic targets, Nat. Biotechnol. 28 (2010) 1069-1078.

    2. [2] L.P. Blair, Q. Yan, Epigenetic mechanisms in commonly occurring cancers, DNA Cell Biol. 31 (2012) S49-S61.[2] L.P. Blair, Q. Yan, Epigenetic mechanisms in commonly occurring cancers, DNA Cell Biol. 31 (2012) S49-S61.

    3. [3] H. Lehrmann, L.L. Pritchard, A. Harel-Bellan, et al., Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation, Adv. Cancer. Res. 86 (2002) 41-65.[3] H. Lehrmann, L.L. Pritchard, A. Harel-Bellan, et al., Histone acetyltransferases and deacetylases in the control of cell proliferation and differentiation, Adv. Cancer. Res. 86 (2002) 41-65.

    4. [4] O. Witt, H.E. Deubzer, T. Milde, I. Oehme, HDAC family: what are the cancer relevant targets, Cancer Lett. 277 (2009) 8-21.[4] O. Witt, H.E. Deubzer, T. Milde, I. Oehme, HDAC family: what are the cancer relevant targets, Cancer Lett. 277 (2009) 8-21.

    5. [5] A.A. Lane, B.A. Chabner, Histone deacetylase inhibitors in cancer therapy, J. Clin. Oncol. 27 (2009) 5459-5468.[5] A.A. Lane, B.A. Chabner, Histone deacetylase inhibitors in cancer therapy, J. Clin. Oncol. 27 (2009) 5459-5468.

    6. [6] B.E. Gryder, Q.H. Sodji, A.K. Oyelere, Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed, Future Med. Chem. 4 (2012) 505-524.[6] B.E. Gryder, Q.H. Sodji, A.K. Oyelere, Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed, Future Med. Chem. 4 (2012) 505-524.

    7. [7] P.A. Marks, The clinical development of histone deacetylase inhibitors as targeted anticancer drugs, Expert Opin. Invest. Drugs 19 (2010) 1049-1066.[7] P.A. Marks, The clinical development of histone deacetylase inhibitors as targeted anticancer drugs, Expert Opin. Invest. Drugs 19 (2010) 1049-1066.

    8. [8] H.S. Wang, B.W. Dymock, New patented histone deacetylase inhibitors, Expert Opin. Ther. Pat. 19 (2009) 1727-1757.[8] H.S. Wang, B.W. Dymock, New patented histone deacetylase inhibitors, Expert Opin. Ther. Pat. 19 (2009) 1727-1757.

    9. [9] M. Paris, M. Porcelloni, M. Binaschi, D. Fattori, Histone deacetylase inhibitors: from bench to clinic, J. Med. Chem. 51 (2008) 1505-1529.[9] M. Paris, M. Porcelloni, M. Binaschi, D. Fattori, Histone deacetylase inhibitors: from bench to clinic, J. Med. Chem. 51 (2008) 1505-1529.

    10. [10] P.A. Marks, Discovery and development of SAHA as an anticancer agent, Oncogene 26 (2007) 1351-1356.[10] P.A. Marks, Discovery and development of SAHA as an anticancer agent, Oncogene 26 (2007) 1351-1356.

    11. [11] C. Campas-Moya, Romidepsin for the treatment of cutaneous T-cell lymphoma, Drugs Today 45 (2009) 787-795.[11] C. Campas-Moya, Romidepsin for the treatment of cutaneous T-cell lymphoma, Drugs Today 45 (2009) 787-795.

    12. [12] P.A. Cassier, A. Lefranc, E.Y. Amela, et al., A phase Ⅱ trial of panobinostat in patients with advanced pretreated soft tissue sarcoma: a study from the French Sarcoma Group, Br. J. Cancer 19 (2013) 909-914.[12] P.A. Cassier, A. Lefranc, E.Y. Amela, et al., A phase Ⅱ trial of panobinostat in patients with advanced pretreated soft tissue sarcoma: a study from the French Sarcoma Group, Br. J. Cancer 19 (2013) 909-914.

    13. [13] J.A. Plumb, P.W. Finn, R.J. Williams, et al., Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101, Mol. Cancer Ther. 2 (2003) 721-728.[13] J.A. Plumb, P.W. Finn, R.J. Williams, et al., Pharmacodynamic response and inhibition of growth of human tumor xenografts by the novel histone deacetylase inhibitor PXD101, Mol. Cancer Ther. 2 (2003) 721-728.

    14. [14] A.R. Razak, S.J. Hotte, L.L. Siu, et al., Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours, Br. J. Cancer 104 (2011) 756-762.[14] A.R. Razak, S.J. Hotte, L.L. Siu, et al., Phase I clinical, pharmacokinetic and pharmacodynamic study of SB939, an oral histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumours, Br. J. Cancer 104 (2011) 756-762.

    15. [15] C. Doñas, M. Fritz, V. Manríquez, et al., Trichostatin A promotes the generation and suppressive functions of regulatory T cells, Clin. Dev. Immunol. (2013) 679-804.[15] C. Doñas, M. Fritz, V. Manríquez, et al., Trichostatin A promotes the generation and suppressive functions of regulatory T cells, Clin. Dev. Immunol. (2013) 679-804.

    16. [16] K. Rao-Bindal, N.V. Koshkina, J. Stewart, et al., The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases, Curr. Cancer Drug Targets 13 (2013) 411-422.[16] K. Rao-Bindal, N.V. Koshkina, J. Stewart, et al., The histone deacetylase inhibitor, MS-275 (entinostat), downregulates c-FLIP, sensitizes osteosarcoma cells to FasL, and induces the regression of osteosarcoma lung metastases, Curr. Cancer Drug Targets 13 (2013) 411-422.

    17. [17] Y. Boumber, A. Younes, G. Garcia-Manero, Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor, Expert Opin. Investig. Drugs 20 (2011) 823-829.[17] Y. Boumber, A. Younes, G. Garcia-Manero, Mocetinostat (MGCD0103): a review of an isotype-specific histone deacetylase inhibitor, Expert Opin. Investig. Drugs 20 (2011) 823-829.

    18. [18] T.A. Miller, D.J. Witter, S. Belvedere, Histone deacetylase inhibitors, J. Med. Chem. 46 (2003) 5097-5116.[18] T.A. Miller, D.J. Witter, S. Belvedere, Histone deacetylase inhibitors, J. Med. Chem. 46 (2003) 5097-5116.

    19. [19] Z.H. Zhao, M.H. Moghadasian, Chemistry, natural sources, dietary intake and pharmacokinetic properties of ferulic acid: a review, Food Chem. 109 (2008) 691-702.[19] Z.H. Zhao, M.H. Moghadasian, Chemistry, natural sources, dietary intake and pharmacokinetic properties of ferulic acid: a review, Food Chem. 109 (2008) 691-702.

    20. [20] M.D. Lu, X. Zhou, Y.J. Yu, et al., Synthesis and in vitro biological evaluation of nitric oxide-releasing derivatives of hydroxylcinnamic acids as anti-tumor agents, Chin. Chem. Lett. 24 (2013) 415-418.[20] M.D. Lu, X. Zhou, Y.J. Yu, et al., Synthesis and in vitro biological evaluation of nitric oxide-releasing derivatives of hydroxylcinnamic acids as anti-tumor agents, Chin. Chem. Lett. 24 (2013) 415-418.

    21. [21] A. Ghasemzadeh, H.Z. Jaafar, E. Karimi, Involvement of salicylic acid on antioxidant and anticancer properties, anthocyanin production and chalcone synthase activity in ginger (Zingiber officinale Roscoe) varieties, Int. J. Mol. Sci. 13 (2012) 14828-14844.[21] A. Ghasemzadeh, H.Z. Jaafar, E. Karimi, Involvement of salicylic acid on antioxidant and anticancer properties, anthocyanin production and chalcone synthase activity in ginger (Zingiber officinale Roscoe) varieties, Int. J. Mol. Sci. 13 (2012) 14828-14844.

    22. [22] J. Sonnemann, I. Hü ls, M. Sigler, et al., Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells, Oncol. Rep. 20 (2008) 219-224.[22] J. Sonnemann, I. Hü ls, M. Sigler, et al., Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells, Oncol. Rep. 20 (2008) 219-224.

    23. [23] The data of selected compounds. 9b: Yield 46%, mp 111-114 ℃; MS (ESI): m/z 387[M + H]+; 1H NMR (300 MHz, DMSO-d6): δ 10.45 (s, 1H), 8.96 (s, 1H), 7.66-7.78 (m, 2H), 7.42 (d, 1H, J = 16.2 Hz), 6.78-7.12 (m, 5H), 6.38 (d, 1H, J = 16.2 Hz), 4.12 (t, 2H, J = 4.5 Hz), 3.83 (s, 3H), 3.62 (t, 2H, J = 4.5 Hz), 1.96-2.21 (m, 2H); Anal. Calcd. for C20H22N2O6: C, 62.17; H, 5.74; N, 7.25; Found: C, 62.28; H, 5.56; N, 7.13. 9c: Yield 52%, mp 102-104 ℃; MS (ESI): m/z 401 [M + H]+; 1H NMR (300 MHz, DMSO-d6): δ 10.41 (s, 1H), 8.89 (s, 1H), 7.65-7.77 (m, 2H), 7.40 (d, 1H, J = 16.2 Hz), 6.73-7.15 (m, 5H), 6.35 (d, 1H, J = 16.2 Hz), 4.10 (t, 2H, J = 4.5 Hz), 3.80 (s, 3H), 3.59 (t, 2H, J = 4.5 Hz), 1.75-1.98 (m, 4H); Anal. Calcd. for C21H24N2O6: C, 62.99; H, 6.04; N, 7.00; Found: C, 62.85; H, 4.96; N, 7.13. 9d: Yield 38%, mp 119-122 ℃; MS (ESI): m/z 387 [M + H]+; 1H NMR (300 MHz, DMSO-d6): δ 10.44 (s, 1H), 7.68-7.79 (m, 2H), 7.45 (d, 1H, J = 16.2 Hz), 6.79-7.21 (m, 5H), 6.39 (d, 1H, J = 16.2 Hz), 4.15 (t, 2H, J = 4.5 Hz), 3.84 (s, 3H), 3.65 (t, 2H, J = 4.5 Hz), 3.06 (s, 3H); Anal. Calcd. for C20H22N2O6: C, 62.17; H, 5.74; N, 7.25; Found: C, 62.03; H, 5.86; N, 7.17. 9e: Yield 47%, mp 108-111 ℃; MS (ESI): m/z 401 [M + H]+; 1H NMR (300 MHz, DMSO-d6): δ 10.42 (s, 1H), 7.65-7.78 (m, 2H), 7.43 (d, 1H, J = 16.2 Hz), 6.76-7.19 (m, 5H), 6.37 (d, 1H, J = 16.2 Hz), 4.13 (t, 2H, J = 4.5 Hz), 3.81 (s, 3H), 3.64 (t, 2H, J = 4.5 Hz), 3.03 (s, 3H), 1.98-2.23 (m, 2H); Anal. Calcd. for C21H24N2O6: C, 62.99; H, 6.04; N, 7.00; Found: C, 63.07; H, 6.26; N, 7.16. 9f: Yield 55%, mp 103-106 ℃; MS (ESI): m/z 415[M + H]+; 1H NMR (300 MHz, DMSO-d6): δ 10.47 (s, 1H), 7.63-7.77 (m, 2H), 7.40 (d, 1H, J = 16.2 Hz), 6.73-7.17 (m, 5H), 6.34 (d, 1H, J = 16.2 Hz), 4.10 (t, 2H, J = 4.5 Hz), 3.79 (s, 3H), 3.61 (t, 2H, J = 4.5 Hz), 3.02 (s, 3H), 1.78-2.02 (m, 4H); Anal. Calcd. for C22H26N2O6: C, 63.76; H, 6.32; N, 6.76; Found: C, 63.57; H, 6.56; N, 7.59. 9h: Yield 57%, mp 95-98 ℃; MS (ESI): m/z 415 [M + H]+; 1H NMR (300 MHz, DMSO-d6): δ 10.39 (s, 1H), 7.59-7.75 (m, 2H), 7.38 (d, 1H, J = 16.2 Hz), 6.70-7.16 (m, 5H), 6.32 (d, 1H, J = 16.2 Hz), 4.07 (t, 2H, J = 4.5 Hz), 3.80 (s, 3H), 3.57 (t, 2H, J = 4.5 Hz), 3.00 (s, 3H), 1.95-2.22 (m, 2H); Anal. Calcd. for C22H26N2O6: C, 63.76; H, 6.32; N, 6.76; Found: C, 63.53; H, 6.48; N, 7.62.[23] The data of selected compounds. 9b: Yield 46%, mp 111-114 ℃; MS (ESI): m/z 387[M + H]+; 1H NMR (300 MHz, DMSO-d6): δ 10.45 (s, 1H), 8.96 (s, 1H), 7.66-7.78 (m, 2H), 7.42 (d, 1H, J = 16.2 Hz), 6.78-7.12 (m, 5H), 6.38 (d, 1H, J = 16.2 Hz), 4.12 (t, 2H, J = 4.5 Hz), 3.83 (s, 3H), 3.62 (t, 2H, J = 4.5 Hz), 1.96-2.21 (m, 2H); Anal. Calcd. for C20H22N2O6: C, 62.17; H, 5.74; N, 7.25; Found: C, 62.28; H, 5.56; N, 7.13. 9c: Yield 52%, mp 102-104 ℃; MS (ESI): m/z 401 [M + H]+; 1H NMR (300 MHz, DMSO-d6): δ 10.41 (s, 1H), 8.89 (s, 1H), 7.65-7.77 (m, 2H), 7.40 (d, 1H, J = 16.2 Hz), 6.73-7.15 (m, 5H), 6.35 (d, 1H, J = 16.2 Hz), 4.10 (t, 2H, J = 4.5 Hz), 3.80 (s, 3H), 3.59 (t, 2H, J = 4.5 Hz), 1.75-1.98 (m, 4H); Anal. Calcd. for C21H24N2O6: C, 62.99; H, 6.04; N, 7.00; Found: C, 62.85; H, 4.96; N, 7.13. 9d: Yield 38%, mp 119-122 ℃; MS (ESI): m/z 387 [M + H]+; 1H NMR (300 MHz, DMSO-d6): δ 10.44 (s, 1H), 7.68-7.79 (m, 2H), 7.45 (d, 1H, J = 16.2 Hz), 6.79-7.21 (m, 5H), 6.39 (d, 1H, J = 16.2 Hz), 4.15 (t, 2H, J = 4.5 Hz), 3.84 (s, 3H), 3.65 (t, 2H, J = 4.5 Hz), 3.06 (s, 3H); Anal. Calcd. for C20H22N2O6: C, 62.17; H, 5.74; N, 7.25; Found: C, 62.03; H, 5.86; N, 7.17. 9e: Yield 47%, mp 108-111 ℃; MS (ESI): m/z 401 [M + H]+; 1H NMR (300 MHz, DMSO-d6): δ 10.42 (s, 1H), 7.65-7.78 (m, 2H), 7.43 (d, 1H, J = 16.2 Hz), 6.76-7.19 (m, 5H), 6.37 (d, 1H, J = 16.2 Hz), 4.13 (t, 2H, J = 4.5 Hz), 3.81 (s, 3H), 3.64 (t, 2H, J = 4.5 Hz), 3.03 (s, 3H), 1.98-2.23 (m, 2H); Anal. Calcd. for C21H24N2O6: C, 62.99; H, 6.04; N, 7.00; Found: C, 63.07; H, 6.26; N, 7.16. 9f: Yield 55%, mp 103-106 ℃; MS (ESI): m/z 415[M + H]+; 1H NMR (300 MHz, DMSO-d6): δ 10.47 (s, 1H), 7.63-7.77 (m, 2H), 7.40 (d, 1H, J = 16.2 Hz), 6.73-7.17 (m, 5H), 6.34 (d, 1H, J = 16.2 Hz), 4.10 (t, 2H, J = 4.5 Hz), 3.79 (s, 3H), 3.61 (t, 2H, J = 4.5 Hz), 3.02 (s, 3H), 1.78-2.02 (m, 4H); Anal. Calcd. for C22H26N2O6: C, 63.76; H, 6.32; N, 6.76; Found: C, 63.57; H, 6.56; N, 7.59. 9h: Yield 57%, mp 95-98 ℃; MS (ESI): m/z 415 [M + H]+; 1H NMR (300 MHz, DMSO-d6): δ 10.39 (s, 1H), 7.59-7.75 (m, 2H), 7.38 (d, 1H, J = 16.2 Hz), 6.70-7.16 (m, 5H), 6.32 (d, 1H, J = 16.2 Hz), 4.07 (t, 2H, J = 4.5 Hz), 3.80 (s, 3H), 3.57 (t, 2H, J = 4.5 Hz), 3.00 (s, 3H), 1.95-2.22 (m, 2H); Anal. Calcd. for C22H26N2O6: C, 63.76; H, 6.32; N, 6.76; Found: C, 63.53; H, 6.48; N, 7.62.

  • 加载中
WeChat 扫一扫看文章
计量
  • PDF下载量:  0
  • 文章访问数:  1318
  • HTML全文浏览量:  10
文章相关
  • 发布日期:  2013-11-27
  • 收稿日期:  2013-08-28
  • 网络出版日期:  2013-11-07
通讯作者: 陈斌, bchen63@163.com
  • 1. 

    沈阳化工大学材料科学与工程学院 沈阳 110142

  1. 本站搜索
  2. 百度学术搜索
  3. 万方数据库搜索
  4. CNKI搜索

/

返回文章

All Rights Reserved by the Chinese Chemical Society   中国化学会 版权所有 京ICP备05002797号

本系统由北京仁和汇智信息技术有限公司开发    技术支持: info@rhhz.net